ProfileGDS5678 / 1450999_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 36% 36% 36% 35% 41% 34% 35% 35% 36% 35% 36% 35% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8398935
GSM967853U87-EV human glioblastoma xenograft - Control 22.8114436
GSM967854U87-EV human glioblastoma xenograft - Control 32.8172136
GSM967855U87-EV human glioblastoma xenograft - Control 42.7591636
GSM967856U87-EV human glioblastoma xenograft - Control 52.7576735
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0400141
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8363234
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7926835
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7774135
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8032536
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7998735
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7832636
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8084535
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8043536